Increasing incidence of prostate cancer in Taiwan A study of related factors using a nationwide health and welfare database

被引:15
作者
Lin, Po-Hung [1 ,2 ,3 ]
Chang, Su-Wei [4 ,5 ]
Tsai, Ling-Hsuan [6 ]
Kan, Hung-Chenq [1 ]
Liu, Jui-Ming [7 ,8 ,9 ]
Chuang, Cheng-Keng [1 ]
Pang, See-Tong [1 ]
Yu, Kai-Jie [1 ,3 ,10 ,11 ]
机构
[1] Chang Gung Mem Hosp Linkou, Dept Surg, Div Urol, 5 Fuzing St, Taoyuan 333, Taiwan
[2] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan, Taiwan
[3] Chang Gung Univ, Sch Med, Coll Med, Taoyuan 333, Taiwan
[4] Chang Gung Univ, Clin Informat & Med Stat Res Ctr, Coll Med, Taoyuan, Taiwan
[5] Chang Gung Mem Hosp Linkou, Dept Pediat, Div Allergy Asthma & Rheumatol, Taoyuan, Taiwan
[6] Chang Gung Univ, Res Serv Ctr Hlth Informat, Taoyuan, Taiwan
[7] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan
[8] Minist Hlth & Welf, Dept Surg, Taoyuan Gen Hosp, Div Urol, Taoyuan, Taiwan
[9] Natl Yang Ming Univ, Dept Med, Taipei, Taiwan
[10] Natl Taipei Univ Technol, Dept Chem Engn & Biotechnol, 5 Fuxing St, Taipei 333, Taiwan
[11] Natl Taipei Univ Technol, Grad Inst Biochem & Biomed Engn, 5 Fuxing St, Taipei 333, Taiwan
关键词
incidence of prostate cancer; metabolic syndrome; prostate cancer; PSA screening; METABOLIC SYNDROME; ANTIGEN; MORTALITY; OVERDIAGNOSIS; PROGRESSION; PATTERNS;
D O I
10.1097/MD.0000000000022336
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the past decades, the incidence of prostate cancer in Taiwan kept rising. Many possible factors including the utility of prostate specific antigen tests, lifestyle remodeling, and patient's comorbidities may contribute to the increasing of incidence or prostate cancer. We aim to use the nationwide Health and Welfare Database (HWD) to investigate possible associated factors. We used HWD, a nationwide database of medical information, to assess the incidence of prostate cancer, utilization of prostate-specific antigen (PSA) test, and underlying diseases of patients and to evaluate whether there was a common trend among these factors. In total, 32,508 patients with newly diagnosed prostate cancer from 2006 to 2013 were identified. The incidence rate of prostate cancer per 100,000 men increased from 35.47 in 2006 to 52.87 in 2012. The number of patients with prostate cancer and underlying diseases related to metabolic syndrome increased every year. The number of total PSA tests and patients undergoing PSA testing, as well as average times of PSA testing per person in the whole population, increased every year. The average PSA test times of patients with newly diagnosed prostate cancer within 3 years before the diagnosis of prostate cancer also increased every year. There was a high correlation between the average PSA test times and the number of patients with newly diagnosed prostate cancer (r(2) = 0.9734). The trends of incidence of prostate cancer, utilization of PSA testing, and underlying diseases related to metabolic syndrome at the diagnoses of cancer were similar, increasing every year in the study period. The results suggested that increasing use of PSA tests may increase the diagnosis of prostate cancers. Underlying diseases related to metabolic syndrome might also affect the incidence of prostate cancer.
引用
收藏
页数:7
相关论文
共 29 条
  • [1] Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men
    Agalliu, Ilir
    Weiss, Noel S.
    Lin, Daniel W.
    Stanford, Janet L.
    [J]. CANCER CAUSES & CONTROL, 2007, 18 (09) : 931 - 937
  • [2] Akbari H, 2019, ARCH IRAN MED, V22, P733
  • [3] Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer
    Ankerst, Donna Pauler
    Gelfond, Jonathan
    Goros, Martin
    Herrera, Jesus
    Strobl, Andreas
    Thompson, Ian M., Jr.
    Hernandez, Javier
    Leach, Robin J.
    [J]. JOURNAL OF UROLOGY, 2016, 196 (02) : 355 - 360
  • [4] Racial Differences in Risk of Prostate Cancer Associated With Metabolic Syndrome
    Beebe-Dimmer, Jennifer L.
    Nock, Nora L.
    Neslund-Dudas, Christine
    Rundle, Andrew
    Bock, Cathryn H.
    Tang, Deliang
    Jankowski, Michelle
    Rybicki, Benjamin A.
    [J]. UROLOGY, 2009, 74 (01) : 185 - 190
  • [5] Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study
    Carlsson, Sigrid
    Assel, Melissa
    Ulmert, David
    Gerdtsson, Axel
    Hugosson, Jonas
    Vickers, Andrew
    Lilja, Hans
    [J]. EUROPEAN UROLOGY, 2017, 71 (01) : 46 - 52
  • [6] Etzioni R, 2002, J NATL CANCER I, V94, P981
  • [7] A Western Dietary Pattern Increases Prostate Cancer Risk: A Systematic Review and Meta-Analysis
    Fabiani, Roberto
    Minelli, Liliana
    Bertarelli, Gaia
    Bacci, Silvia
    [J]. NUTRIENTS, 2016, 8 (10)
  • [8] Meta-analysis of metabolic syndrome and prostate cancer
    Gacci, M.
    Russo, G. I.
    De Nunzio, C.
    Sebastianelli, A.
    Salvi, M.
    Vignozzi, L.
    Tubaro, A.
    Morgia, G.
    Serni, S.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (02) : 146 - 155
  • [9] Gann Peter H, 2002, Rev Urol, V4 Suppl 5, pS3
  • [10] Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications
    Gershman, Boris
    Van Houten, Holly K.
    Herrin, Jeph
    Moreira, Daniel M.
    Kim, Simon P.
    Shah, Nilay D.
    Karnes, R. Jeffrey
    [J]. EUROPEAN UROLOGY, 2017, 71 (01) : 55 - 65